Close
Description
Diseases of the CNS are notoriously difficult to treat and have been a minefield of disasters in the pharma industry for a number of years. However, this is still an immensely important area made more so by an ageing population. There is new hope and new initiatives as advances in neuroscience are made.
This module addresses the molecular basis of selected neurological conditions, the animal and cellular models that are used to investigate these conditions, novel therapies such as CNS tissue engineering and gene therapy and the drug targets that have been/are being used in the development of lead compounds and drug molecules.
Neurotransmitter receptor proteins are a major target for drug action within the central nervous system (CNS). CNS drug discovery programmes have been revolutionized during the last ten years with the realization that rather than a single neurotransmitter receptor existing per neurotransmitter, multiple highly homologous neurotransmitter receptor subtypes exist for each inhibitory and excitatory neurotransmitter. Therefore, the challenge is to develop receptor subtype-selective therapeutic compounds with the hope that this new generation of drugs will have unique and selective therapeutic properties while reducing unwanted adverse effects
听
Module deliveries for 2024/25 academic year
Last updated
This module description was last updated on 8th April 2024.
听